Some of the emerging therapeutics to modulate NRP1 function have provided useful tools for experimental investigation and have clinical potential to treat ocular neovascular diseases such as retinopathy of prematurity (ROP), proliferative diabetic retinopathy (PDR) and age-related macular degeneration (AMD) (Foster and Resnikoff, 2005). The gene discussed is NRP1; the disease is age-related macular degeneration.